Correction to: British Journal of Cancer (2016) 115, 789–796. doi:10.1038/bjc.2016.271
Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in one of their affiliations. The authors would like to apologise for this mistake. The correct affiliation for Andrés J Muñoz Martín is ‘Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.’
Change history
25 October 2016
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/bjc.2016.271
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
About this article
Cite this article
Dalgleish, A., Stebbing, J., Adamson, D. et al. Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 115, e16 (2016). https://doi.org/10.1038/bjc.2016.342
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2016.342
This article is cited by
-
ANTONIO-Studie
Forum (2023)
-
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity
Journal of Translational Medicine (2018)
-
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
Journal of Hematology & Oncology (2018)
